Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck And Pfizer Make A Late Play For The Diabetes Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Two of the world’s largest pharmaceutical companies are teaming up to develop a treatment for type 2 diabetes, but the drug will have plenty of competitors with a better market position by the time it faces regulatory approval.

You may also be interested in...

Pfizer To Spend 2016 Playing Catch Up In Big Therapeutic Categories

The big pharma reported the first positive Phase III data for its PCSK9 inhibitor bococizumab and confirmed it is on track to file the SGLT2 inhibitor ertugliflozin in the US this year, but both drugs will compete in markets already crowded with rivals. The same is true for its PD-L1 inhibitor avelumab.

Divestiture Possible For Merck’s Animal Health, Consumer Units; Januvia’s Sales Slide

The performance of Merck’s diabetes franchise came under scrutiny by analysts on an earnings call Oct 28, after the company reported sales of its number one drug fell 5% in the third quarter year on year. Top executives came closer than ever to saying they are inclined to divest non-core businesses, including animal health.

Lilly Bullish On Diabetes/Oncology Products; Analysts Skeptical

The Indianapolis-based big pharma touted the value of its late-stage pipeline at an analyst meeting on Oct. 3, particularly its diabetes and oncology franchises, even though they face tough competition and have encountered some setbacks.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts